Priced like the old business, running like a new one: management is redirecting the call away from the metric investors
The model's full reasoning — Q3 2018 call → NOThe question asks whether management repeatedly redirects attention away from the conventional yardstick toward a different part of the business that is already earning today, and indicates that this different part is not yet reflected in reported results. Let me analyze the transcript. The company is Agios Pharmaceuticals, which has two IDH inhibitors: IDHIFA (enasidenib) and TIBSOVO (ivosidenib). The conventional yardstick for this company would be the IDH inhibitor franchise, particularly the launch of TIBSOVO in relapsed/refractory AML. Looking at the call, the discussion is organized around: - TIBSOVO launch progress (Steve Hoerter's commercial update) - Clinical development programs (Chris Bowden) - Financial results (Andrew Hirsch) The questions from analysts focus on: - TIBSOVO revenues and launch trajectory - Duration of therapy - Clinical trial timelines - AG-270 program - AGILE trial enrollment Is there any point where management sets aside the conventional yardstick and points to a different part of the business that is already earning? The call is largely a conventional earnings call organized around the company's usual metrics: TIBSOVO sales, clinical development progress, financial results. Management discusses the launch, the clinical pipeline, and financials. There's no clear instance where management says "the thing you're watching is no longer the right thing" and points to a different part of the business that is already earning but not yet reflected in results. The discussion is about the current launch, clinical trials, and pipeline - all standard for a biotech earnings call. The pipeline programs (AG-270, AG-636, mitapivat) are prospective - they're in development, not yet earning. The TIBSOVO launch is the current revenue driver and is being discussed as such. There's no redirection from a conventional yardstick to a different earning part of the business. The call is a standard earnings call organized around the company's usual metrics and drivers. Answer: NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
SPT · Q2 2023 → YESThe question is whether management repeatedly redirects attention away from the conventional measure toward a different part of the business that's already earning today, and indicates that this diffe...YES The transcript shows management repeatedly reframing away from the conventional total ARR/revenue growth metric (which is being distorted by unpredictable low-end non-core ARR) toward the higher-quality up-market/enterprise segment that is already delivering record new business ACVs, 50%+ YoY growth, and 43% of 2023 ARR. They explicitly set the low-end aside by removing it from forecasts and modeling to give “greatest visibility,” note that Q2 ARR growth will be the lowest pace of the year because of this change, and indicate the reported figures still reflect the old mix while the new up-market story is already earning today (with Tagger adding further upside not yet reflected). This creates the coherent posture of redirecting attention from the headline growth number outsiders watch to the part of the business that is already producing real results.
WD · Q2 2022 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly reframing the discussion away from the conventional multifamily agency lender yardstick (origination volumes, GSE lending, MSR-driven EPS) toward the diversified services and asset-management businesses that are already generating substantial cash revenue and EBITDA today. They explicitly set the old metric aside by introducing adjusted EPS to “strip out non-cash mortgage servicing rights,” highlight the shift from “lending-centric” to “broader technology-enabled financial services,” and note that segment results now provide “more transparency into our operating structure.” They point to debt brokerage, property sales, SAM (Alliant, Zelman), small-balance lending, and appraisals as the new earning engines, describing their concrete contributions (e.g.
CALX · Q1 2023 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly framing the company as operating in a "new market" centered on platforms, clouds, and managed services—distinct from the legacy hardware/cyclical model—while highlighting real earnings from these areas (e.g., 988 BSPs deploying platforms, 865 cloud customers, 334 with 41 new managed services in Q1, record Intelligent Access EDGE revenue). They indicate this is already producing revenue and customer adoption but remains early-stage ("this is the beginning," "early stage of where we are in this new market"), with reported results still reflecting the prior hardware-focused picture.